WHO Issues Alert Over Acute Lack of Obesity Jabs
Fewer than 10% of patients who could benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it issues its inaugural guidance on the medications.
Considering over a billion individuals worldwide now living with obesity, it is calling for broader and more equitable availability to GLP-1 medication.
According to estimates, over two billion could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a long-term condition that can be treated with comprehensive and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant hurdles to widespread access to the treatments that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Scarcity
Even under the current most optimistic outlook, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of the global need, per the health organization.
The guideline urges countries and companies to expand access, via strategies including voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and increase the sense of being full so individuals reduce food intake.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research indicates users may regain a significant portion after a year of discontinuing the medication, because their normal hunger return.
To be above a healthy weight elevates your likelihood for developing diseases, like type 2 diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts individuals in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.